Ginkgo Bioworks: $800M valuation, IPO Readiness 46, Public. Synthetic biology platform programming cells for agriculture, pharmaceuticals, and materials. Track live on The IPO Stack.
Synthetic biology platform programming cells for agriculture, pharmaceuticals, and materials.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Ginkgo Bioworks IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Ginkgo Bioworks is already a public company.
Ginkgo Bioworks is valued at $800M as of September 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Ginkgo Bioworks is already a public company. You can invest by purchasing shares on public stock exchanges.
Ginkgo Bioworks scores 46/100 (Grade: D) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Ginkgo Bioworks has raised $1.6B in total venture capital and private equity funding, with backing from Soaring Eagle Acquisition Corp, Baillie Gifford, General Atlantic.
Ginkgo Bioworks's notable investors include Soaring Eagle Acquisition Corp, Baillie Gifford, General Atlantic, Bill Gates, Viking Global Investors. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Ginkgo Bioworks is a Biotechnology company. Synthetic biology platform programming cells for agriculture, pharmaceuticals, and materials.